PSS World Medical Rating Lowered to Neutral at Robert W. Baird (PSSI)
PSS World Medical (NASDAQ: PSSI) was downgraded by analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Friday. They currently have a $21.00 price target on the stock, down from their previous price target of $29.00.
Separately, analysts at Raymond James (NYSE: RJF) downgraded shares of PSS World Medical from an “outperform” rating to a “market perform” rating in a research note to investors on Thursday.
Shares of PSS World Medical traded down 3.05% during mid-day trading on Friday, hitting $20.00. PSS World Medical has a 52 week low of $18.51 and a 52 week high of $29.47. The company has a market cap of $1.004 billion and a P/E ratio of 14.95.
PSS World Medical last announced its earnings results on Thursday, May 10th. The company reported $0.38 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.43 by $0.05. The company’s quarterly revenue was down 2.0% on a year-over-year basis. On average, analysts predict that PSS World Medical will post $0.37 earnings per share next quarter.
PSS World Medical, Inc. (PSSI) is a distributor of medical products and equipment, pharmaceutical products, healthcare information technology and billing services to alternate-site healthcare providers, including physician offices, long-term care and assisted living facilities, home healthcare and hospice providers.